Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

Inclusion Criteria:

* Histologically proven cancer.
* Written informed consent.
* Age \>/= 18 years.
* Life expectancy of at least 12 weeks.
* World Health Organization (WHO) performance status of 0 or 1.
* Adequate Hematological and biochemical indices to support investigational therapy.
* All women of childbearing potential (WOCBP) must have a negative serum pregnancy test.
* WOCBP and fertile men and their partners must agree to use an effective form of contraception during the study and for 90 days after the last dose of study medication.
* Measurable and evaluable disease.
* All toxic manifestations of previous treatment must have resolved.
* Able to undergo MRI scanning.

Exclusion Criteria:

* Radiotherapy, endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosureas and Mitomycin-C) prior to treatment.
* Pregnant and lactating women.
* Major thoracic and/or abdominal surgery in the preceding four weeks from which the patient has not yet recovered.
* Patients which have active uncontrolled infections.
* Patients with any other condition that in the Investigator's opinion would not make the patient a good candidate for the clinical trial.
* Patients known to be serologically positive for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV).
* Previous or ongoing cardiac conditions.
* Uncontrolled hypertension.
* Patients taking any drug known to prolong the QTc interval.
* Patients who have had any ischaemic or vascular damage from previous radiotherapy.
* Patients taking warfarin or heparin.
* Patients taking naproxen.
* Patients taking supplements or multivitamins containing vitamin C.
* Patients should not be taking any other investigational drug for the duration of the study.
* Patients with brain metastases or neurological tissue involvement of the spinal column.